x

¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

Indexada en:

Index Medicus/Medline, Latindex, IBECS, IME, SCOPUS y MEDES

Métricas

  • SCImago Journal Rank (SJR):0,138
  • Source Normalized Impact per Paper (SNIP):0,141
Semergen 2004;30:190-2 - DOI: 10.1016/S1138-3593(04)74299-9
Terapia antiandrogénica como quimioprevención del cáncer de próstata
D. Subirá Ríosa, E. Alonso Sandoicab,, J.I. Martínez Salamancaa, J. Jara Rascóna, C. Hernández Fernándeza
a Servicio de Urología. Hospital General Universitario Gregorio Marañón. Madrid
b Centro de Salud Hermanos García Noblejas. Área 4. Madrid
Recibido 26 mayo 2003, Aceptado 11 noviembre 2003
Resumen

Hormonal deprivation produced by the 5-alpha-reductase inhibitors on the prostatic tissue has suggested the possibility that agents such as finasteride may play some role in the prevention of prostate cancer.

The present article presents a case of prostatic interepithelial neoplasm (PIN) treated for its accompanying benign prostatic hyperplasia with finasteride, that evolved to biopsied prostatic atrophy. The action mechanism of this type of anti-androgenic therapy in these dysplasias is discussed and the prevent literature on its possible effect in the reduction of the risk of prostate cancer is reviewed.

Palabras clave
cáncer de próstata, prevención, finasteride
Key words
prostate cancer, prevention, finasteride
El Texto completo solo está disponible en PDF
Bibliografía
1.
T.M. Seay,I.M. Thompson
Screening for carcinoma of the prostate. Progress and problems
Cancer of the prostate, pp. 119-146
2.
R. Liebermen
Androgen deprivation therapy for prostate cancer chemoprevention: Current status and future directions for agent development
Urology, 58 (2001), pp. 83-90
3.
S.A. Kaplan
5 alpha-reductase inhibitors: What role should they play?
Urology, 58 (2001), pp. 65-70
4.
R.J. Cote,E.C. Skinner,C.E. Salem
The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels
Br J Cancer, 78 (1998), pp. 413-418
5.
X.J. Yang,K. Lecksell,K. Short
Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy?
Urology, 53 (1999), pp. 696-700
6.
D.G. Bostwick,J.Q. Qian
Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia
Urology, 58 (2001), pp. 91-93
7.
P.S. Nelson,T.P. Gleason,M.K. Brawer
Chemoprevention for prostatic intraepithelial neoplasia
Eur Urology, 30 (1996), pp. 269-278
8.
M. Bologna,C. Vicentini,C. Festuccia
Inhibition of invasive capacity of prostatic carcinoma primary cultures by finasteride
Eur Urol, 35 (1999), pp. 76
9.
J.W. Aquilina,J.J. Lipsky,D.G. Bostwick
Androgen deprivation as a strategy for prostate cancer chemoprevention
J Natl Cancer Inst, 89 (1997), pp. 689-696
10.
C.G. Roehrborn,J. McConnell,J. Bonilla
Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. Proscar long-term efficacy and safety study
J Urol, 163 (2000), pp. 13-20
11.
P. Feigl,B. Blumenstein,I.M. Thompson
Design of the prostate cancer prevention trial (PCPT)
Controlled Clin Trials, 16 (1995), pp. 150-163
12.
I.M. Thompson,P.h.J. Goodman,C.M. Tangen
Influence of finasteride in the development of prostatic cancer
N Engl J Med, 349 (2003), pp. 215-224 http://dx.doi.org/10.1056/NEJMoa030660
Correspondencia: E. Alonso Sandoica. C/ Condado de Treviño, 2, p-1, 5.°-C. 28033 Madrid
Copyright © 2004. Elsevier Espa??a, S.L. y Sociedad Espa??ola de Medicina Rural y Generalista (SEMERGEN)